drugset / Trial / NCT00225251
Wellbutrin XL for Dysthymic Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.
Timeline
- Start
- 2004-11
- Primary completion
- 2008-05
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 150 mg | — |
| Subject | Bupropion | Small molecule | 450 mg | — |